# Docetaxel in Node Positive Adjuvant Breast Cancer

> **NCT00688740** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 1491 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** 5-fluorouracil
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00688740
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-06
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 1491 (ACTUAL)
- **Last updated:** 2011-02-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00688740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00688740, "Docetaxel in Node Positive Adjuvant Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00688740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*